Sei Investments Co. Sells 30,064 Shares of Axonics, Inc. (NASDAQ:AXNX)

Sei Investments Co. lowered its holdings in shares of Axonics, Inc. (NASDAQ:AXNX) by 89.5% in the 2nd quarter, Holdings Channel.com reports. The fund owned 3,533 shares of the company’s stock after selling 30,064 shares during the period. Sei Investments Co.’s holdings in Axonics were worth $237,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Alpine Associates Management Inc. raised its stake in shares of Axonics by 16.2% during the second quarter. Alpine Associates Management Inc. now owns 2,108,871 shares of the company’s stock valued at $141,779,000 after acquiring an additional 294,100 shares during the last quarter. Magnetar Financial LLC increased its position in shares of Axonics by 218.3% during the first quarter. Magnetar Financial LLC now owns 1,146,019 shares of the company’s stock worth $79,041,000 after buying an additional 785,981 shares during the period. KRYGER CAPITAL Ltd acquired a new position in shares of Axonics during the first quarter valued at about $65,211,000. Goldman Sachs Group Inc. grew its holdings in shares of Axonics by 6.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 621,570 shares of the company’s stock valued at $38,680,000 after buying an additional 40,306 shares during the last quarter. Finally, Hsbc Holdings PLC grew its holdings in shares of Axonics by 26.5% during the second quarter. Hsbc Holdings PLC now owns 322,853 shares of the company’s stock valued at $21,715,000 after buying an additional 67,603 shares during the last quarter. Institutional investors own 99.48% of the company’s stock.

Insider Transactions at Axonics

In related news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the sale, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.85% of the company’s stock.

Axonics Stock Performance

Shares of NASDAQ:AXNX opened at $70.30 on Friday. The stock has a market cap of $3.59 billion, a P/E ratio of -1,757.06 and a beta of 0.82. Axonics, Inc. has a 12 month low of $48.30 and a 12 month high of $70.53. The company has a 50 day moving average of $69.11 and a 200 day moving average of $68.11.

Axonics (NASDAQ:AXNX) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.03. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The company had revenue of $114.57 million during the quarter, compared to analyst estimates of $112.83 million. During the same period in the prior year, the business posted ($0.15) EPS. The firm’s revenue was up 23.3% compared to the same quarter last year. On average, equities analysts forecast that Axonics, Inc. will post 0.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a report on Monday, August 5th. Eight equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Axonics presently has a consensus rating of “Hold” and an average price target of $69.57.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.